Import Abbott Binaxnow Streptococcus Pneumoniae — Buy in wholesale FOB from Supplier in India

The Abbott BinaxNOW Streptococcus pneumoniae Antigen Card is a rapid immunochromatographic assay for the qualitative detection of S. pneumoniae capsular polysaccharide antigen in urine and cerebrospinal fluid (CSF) specimens. The test employs monoclonal antibody-coated membrane technology to capture pneumococcal antigen, producing visually interpreted results in 15 minutes at point-of-care or laboratory settings without specialized instrumentation. Each kit contains 22 test cards (catalog 710000) and targets two distinct clinical presentations: pneumococcal pneumonia (urine specimen) and pneumococcal meningitis (CSF specimen). The India-origin supply positions this listing for South Asian regional procurement, re-export to adjacent markets, and cost-sensitive institutional buyers.

The immunochromatographic membrane is coated with monoclonal antibodies specific to S. pneumoniae capsular polysaccharide, a complex antigenic target present in multiple serotypes. Performance validation demonstrates 86 percent sensitivity and 94 percent specificity in urine, with 97 percent sensitivity and 99 percent specificity in CSF. These figures position the assay as an adjunct to culture and molecular methods, particularly where antibiotic pretreatment reduces culture yield or where rapid therapeutic decisions are clinically critical. The test does not replace definitive culture or PCR identification, nor does it provide serotype information relevant to vaccine coverage assessment. Standard handling requires room temperature storage with protection from extreme heat and humidity to preserve antibody conjugate stability.

Clinical laboratories, hospital emergency departments, and diagnostic reference centers constitute the primary buyer segments, particularly in regions with significant pneumococcal disease burden and limited molecular diagnostic access. The 15-minute result time supports emergency department triage and intensive care unit decision-making for suspected meningitis cases. Importers should recognize that this in vitro diagnostic device requires appropriate import licensing under India's Medical Device Rules and equivalent regulations in destination countries. Cold chain is not required, which simplifies logistics compared to culture-based transport media or molecular reagent kits. Buyers must confirm current manufacturing origin, as Abbott maintains multiple production sites and regulatory dossiers may vary by release region.

Saaskin Corporation Private Limited operates from No. 275/184, First Floor, Office No. 2, Golden Enclave, Periyar E.V.R. Salai, PH Road, Kilpauk, Chennai, 600010, Tamil Nadu, India. The supplier holds a Harbor trust tier classification. No response rate is recorded (0.00 percent with zero average response hours), indicating that direct communication testing before order commitment is prudent. The company profile does not state years incorporated, annual turnover, employee count, or specific clientele, so buyers should conduct independent verification through India's Ministry of Corporate Affairs registry and request trade references from prior diagnostic product transactions.

The listing positions Saaskin as a distribution channel for Abbott's regulated diagnostic portfolio, specifically the BinaxNOW S. pneumoniae antigen card for institutional and clinical laboratory supply. No manufacturer authorization certificates are displayed in the extracted data. The Chennai location provides access to Tamil Nadu's pharmaceutical distribution infrastructure and Chennai Port/Madras Airport logistics corridors. Buyers should verify whether Saaskin holds direct Abbott distributor status or sources through authorized tier-two channels, as this affects warranty, lot traceability, and regulatory documentation authenticity for end-market registration.